0.432
0.00 (0.00%)
| Penutupan Terdahulu | 0.432 |
| Jumlah Dagangan | 84,360 |
| Harga / Pendapatan (P/E Ke hadapan) | 42.73 |
| Harga / Jualan (P/S) | 0.470 |
| Harga / Buku (P/B) | 1.43 |
| Julat 52 Minggu |
| Margin Keuntungan | -122.63% |
| Margin Operasi (TTM) | -71.54% |
| EPS Cair (TTM) | -0.260 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 857.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 45.07% |
| Nisbah Semasa (MRQ) | 0.640 |
| Aliran Tunai Operasi (OCF TTM) | -33.17 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 50.39 M |
| Pulangan Atas Aset (ROA TTM) | -28.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -114.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Vaxart, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -2.5 |
| Purata | -1.57 |
|
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.88% |
| % Dimiliki oleh Institusi | 12.08% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Beacon Capital Management, Llc | 31 Dec 2025 | 0 |
| Custos Family Office, Llc | 31 Dec 2025 | 0 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |